samedan logo
 
 
spacer
home > ebr > winter 2002 > the splice of life
PUBLICATIONS
European BioPharmaceutical Review

The Splice of Life

Converting knowledge derived from genomics into therapeutics was never going to be straightforward. Simply knowing the number and sequence of genes in the human genome is not enough. Instead, researchers need to understand the functions of the huge diversity of proteins produced by this genetic code, as proteins are responsible for most cellular activities and form the majority of drug targets.

This is one reason for the huge growth in proteomics research, as researchers try to elucidate cellular events at the level of proteins. However, proteomics requires studies on a far greater scale than genomics. This is due to the vast number of different proteins produced by post-translational modifications, polyadenylation (1) and, perhaps most importantly, the way in which RNA is processed.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Fabien Schweighoffer PhD, Executive Vice-President of Therapeutic Programs at ExonHit Therapeutics Dr Fabien Schweighoffer is one of the founders of ExonHit Therapeutics. Previous to this he was employed as a Research Scientist in the Molecular Biology department of Rhфne-Poulenc Rorer (now Aventis) for 10 years.
Fabien holds a PhD in Biochemistry from the University of Paris, has published many papers and received several awards..

spacer
Dr Fabien Schweighoffer
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

“PACK DIFFERENT” with EMBALLAGE 2008

“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement